NCT07433049 Impact of Supplementation in Improving Metabolic Health Outcomes (ISMOS) Study
| NCT ID | NCT07433049 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Institute for Human Development and Potential (IHDP), Singapore |
| Condition | Glucose Control |
| Study Type | INTERVENTIONAL |
| Enrollment | 400 participants |
| Start Date | 2026-01-20 |
| Primary Completion | 2028-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 400 participants in total. It began in 2026-01-20 with a primary completion date of 2028-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study investigates the role of multivitamin and multimineral (MVM) supplementation in improving metabolic, musculoskeletal, and mental health among midlife Asian women aged 40-60 years, a critical period marked by hormonal and physiological transitions from pre- to post-menopause. Evidence from the GUSTO cohort in Singapore has shown that higher plasma levels of vitamins B6, B9, B12, and D are associated with better metabolic profiles, insulin sensitivity, and mental wellbeing, while deficiencies are linked to increased metabolic and psychological risks. Given that vitamin insufficiency and central obesity are highly prevalent among Asian women even at lower BMI, this randomized, double-blind, placebo-controlled trial will evaluate whether 12 months of daily MVM supplementation can reduce MetaboAge and improve metabolic, mental, and muscle health outcomes compared with placebo. Findings will inform preventive strategies for extending health span and mitigating chronic disease risks among midlife women in Asia.
Eligibility Criteria
Inclusion Criteria: * Women aged 40-60 years old * Chinese, Malay or Indian * BMI between 23.0-35.0 kg/m2 * Proficient in English language * Willing to comply with study protocol \& provide informed consent Exclusion Criteria: * Pregnant or planning a pregnancy * Diagnosis with Diabetes, Polycystic Ovary Syndrome (PCOS), autoimmune diseases, chronic organ failure, severe heart disease, eating disorders and/or other medical conditions which in the PI's judgment which may affect study outcomes * Fasting glucose value ≥ 7.0 mmol/L * Active cancer or treatment of cancer in the last 3 years * Participating in other nutritional intervention studies * Taking oral corticosteroids, anti-psychotic and/or weight loss drugs * Having planned hospitalization in the next 12 months * Planning to have major diet changes in the next 12 months * Taking a medically prescribed supplement(s) that contains 3 or more of the ingredients of the study product * Taking a non-prescribed supplement(s) that contains 3 or more of the ingredients of the study product in the last 1 month
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07433049 clinical trial?
This trial is open to female participants only, aged 40 Years or older, up to 60 Years, studying Glucose Control. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07433049 currently recruiting?
Yes, NCT07433049 is actively recruiting participants. Contact the research team at johan_eriksson@a-star.edu.sg for enrollment information.
Where is the NCT07433049 trial being conducted?
This trial is being conducted at Singapore, Singapore.
Who is sponsoring the NCT07433049 clinical trial?
NCT07433049 is sponsored by Institute for Human Development and Potential (IHDP), Singapore. The trial plans to enroll 400 participants.